# Long-term Safety Study of Alogliptin Used in Combination With Thiazolidine in Participants With Type 2 Diabetes in Japan

> **NCT01318122** · PHASE2,PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 336 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Alogliptin and pioglitazone
- **DRUG:** Alogliptin and pioglitazone

## Key facts

- **NCT ID:** NCT01318122
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 336 (ACTUAL)
- **Last updated:** 2012-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01318122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01318122, "Long-term Safety Study of Alogliptin Used in Combination With Thiazolidine in Participants With Type 2 Diabetes in Japan". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01318122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*